InsiderTrades

Form 4 for ZYME Zymeworks Inc.

Accepted 2026-01-13 00:00:00 ET · period of report 2026-01-12 · accession 0001193125-26-011885 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-01-13 2026-01-12 ZYME Hollywood Mark EVP, COO M - OptEx $0.00 +17.7K 139.0K +15% $0
D 2026-01-13 2026-01-12 ZYME Hollywood Mark EVP, COO S - Sale+OE $22.67 -6,120 132.9K -4% -$138.7K
DM 2026-01-13 2026-01-12 ZYME Hollywood Mark EVP, COO A - Grant $0.00 +183.0K 70.0K New $0
D 2026-01-13 2026-01-12 ZYME Hollywood Mark EVP, COO M - OptEx $0.00 -17.7K 35.3K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-12 M A 17,666 $0.00 139,033 D — — (F1) Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.
2 Common Common Stock 2026-01-12 S D 6,120 $22.67 132,913 D — — (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3 Derivative Restricted Stock Unit 2026-01-12 A A 47,000 $0.00 47,000 D — · — to — 47,000 Common Stock (F4) Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. (F7) RSUs vest in four equal annual installments beginning on first anniversary of grant date.
4 Derivative Performance Stock Unit 2026-01-12 A A 66,000 $0.00 66,000 D — · — to — 66,000 Common Stock (F8) Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. (F9) (Continued from footnote 8) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
5 Derivative Stock Option (Right to Buy) 2026-01-12 A A 70,000 $0.00 70,000 D $23.16 · — to 2036-01-11 70,000 Common Stock (F6) Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
6 Derivative Restricted Stock Unit 2026-01-12 M D 17,666 $0.00 35,334 D — · — to — 17,666 Common Stock (F4) Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. (F5) The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.